Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Academic Article uri icon

Overview

abstract

  • Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.

authors

  • Kucine, Nicole Elena
  • Bergmann, Shayla
  • Krichevsky, Spencer
  • Jones, Devin
  • Rytting, Michael
  • Jain, Juhi
  • Bennett, Carolyn M
  • Resar, Linda M S
  • Mascarenhas, John
  • Verstovsek, Srdan
  • Hoffman, Ronald

publication date

  • December 31, 2020

Research

keywords

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Polycythemia Vera
  • Polyethylene Glycols
  • Thrombocythemia, Essential

Identity

PubMed Central ID

  • PMC9040312

Scopus Document Identifier

  • 85098499722

Digital Object Identifier (DOI)

  • 10.1002/pbc.28888

PubMed ID

  • 33381905

Additional Document Info

volume

  • 68

issue

  • 3